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1. Introduction 
Urinary tract infections (UTIs) are one of the most common medical complications of 
pregnancy (Mittal & Wing, 2005). It is estimated that one in three women of childbearing 
age will have a UTI (Duarte et al., 2008). Because of the normal physiologic changes induced 
by gestation, pregnant women are especially susceptible to these infections.  
UTIs are characterized by the presence of infectious agents in the genito-urinary tract that 
cannot be explained by contamination. These agents have the potential to invade the 
tissues of the urinary tract and adjacent structures. The microbiological profile is well 
known and pathogens such as Escherichia coli have been present in the vast majority of 
cases (Sheffield & Cunningham, 2005). The infection may be limited to the growth of 
bacteria in the urine (which frequently don’t produce symptoms) or it can result in several 
syndromes associated with an inflammatory response to the bacterial invasion. Actually, 
the term UTI represent a wide variety of conditions, including asymptomatic forms of 
UTIs, urethritis, cystitis, acute pyelonephritis and pyelonephritis with bacteremia or 
sepsis (Joseph DiPiro et al.,  2011). 
There are several classification methods for these infections. In this chapter, we will refer to 
UTIs as follows: 
 Asymptomatic bacteriuria is defined as the presence of more than 108 colonies/L of 
urine, without the symptoms of an acute UTI (Schnarr & Smaill, 2008); 
 lower tract infection and upper tract infections, according to the anatomical site of 
contamination (Joseph DiPiro et al.,  2011) ; 
 Lower UTIs: The anatomical site of the infection can be the bladder (cystitis) and/or the 
urethra (urethritis) (Joseph DiPiro et al., 2011);   
 Upper UTIs: The kidneys are the anatomical site of the infection (pyelonephritis 
associated with inflammation of the renal parenchyma, calices and pelvis) 
(Wagenlehner et al., 2009); 
 Uncomplicated UTIs: infections occurring in individuals who lack structural or 
functional abnormalities of the urinary tract that interfere with the normal flow of urine 
or voiding mechanism (Joseph DiPiro et al., 2011); 
 Complicated urinary tract infections: infections occurring in individuals with 
predisposing lesions of the urinary tract that interferes with the normal flow of urine 
and urinary tract defences. Common causes of predisposing lesions are birth defects, 
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kidney stones, catheters, or obstruction (Masson et al., 2009). An UTI during pregnancy 
is considered complicated. 
During gestation, untreated UTIs can lead to several pregnancy complications, such as 
low birth weight infants, premature delivery, and occasionally, stillbirth. Prompt and 
efficacious treatment of symptomatic UTIs is warranted in pregnant women. 
Nevertheless, there is still some controversy regarding the screening and treatment of 
asymptomatic forms during gestation (Lin and Brown 2010; Lumbiganon et al., 2010; 
Schmiemann et al., 2010). 
Given the prevalence and the potential impacts of UTIs on the health of the mother and her 
child, the objective of this chapter is to cover the most important clinical aspects of the 
epidemiology, etiology, physiopathology, pregnancy outcomes, and the treatment risks and 
benefits associated with UTIs during pregnancy. 
2. Epidemiology 
It is estimated that 2 to 10% of pregnant woman suffer from any form of UTIs (Lee et al., 
2008). These infections complicate up to 20% of pregnancies and are responsible for the 
majority of antepartum admissions to the maternal–fetal medicine units (Sheffield & 
Cunningham, 2005).  
The prevalence of asymptomatic forms of UTIs has remained constant across countries, and 
most of the recent observational studies report similar rates, ranging from 2 to 10% - similar 
to that of nonpregnant women (Duarte et al., 2008; Bahadi et al., 2010). Acute cystitis is 
prevalent in 1 to 4% of pregnant women (Wagenlehner et al., 2009).  
Despite the relatively low prevalence of pyelonephritis during pregnancy (0.5 to 2%), it is 
estimated that 20% to 40% of pregnant women with asymptomatic bacteriuria will develop 
this condition later in gestation (Jolley & Wing, 2010).  A study showed that if UTI is left 
untreated, 30% of mothers will develop acute pyelonephritis compared with 1.8% of non-
bacteriuric controls2. Many studies have reported that pyelonephritis is more common 
during the second half of pregnancy, with an incidence peak during the last two trimesters 
of pregnancy (Gilstrap et al., 1981; Hill et al., 2005; Sharma & Thapa, 2007). Acute 
pyelonephritis may lead to adverse outcomes for the baby and the mother, such as 
premature delivery, low birth weight infants, preeclampsia, hypertension, renal failure and 
fetal death (Hill et al., 2005). 
The prevalence of UTI in pregnancy is closely related to socioeconomic factors (Turck et al., 
1962). Predictors of UTIs’ asymptomatic forms include: welfare status, increasing maternal 
age, multiparity, risky sexual behavior, history of childhood UTIs and history of recurrent 
UTIs. It has been reported that indigent women have a five-fold greater incidence of 
bacteriuria than non-indigent populations (Turck et al., 1962; Golan et al., 1989). The 
prevalence is also markedly increased if women present certain pre-existing medical 
conditions, such as diabetes mellitus, sickle cell disease, immuno-deficiency states, urinary 
tract anatomic anomalies, spinal cord injuries and psychiatric illnesses (Ovalle et al., 1989). 
Nevertheless, there is some controversy on the effects of these host factors as predictors of 
UTIs (Fatima & Ishrat, 2006). UTI before pregnancy is a predictor for the diagnosis of 
asymptomatic bacteriuria at the first prenatal visit (Tugrul et al., 2005). Risk factors for 
developing cystitis and pyelonephritis in pregnancy include those stated before, as well as a 
history of Clamidia trachomatis infection, illicit drug use, and having less than 12 years of 
education (Verani et al., 2010). 
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It was suggested that UTIs screening and testing algorithms should be designed, 
incorporating identified risk factors in order to lower overall costs and to improve maternal 
and infant outcomes (Chng & Hall, 1982; Pastore et al., 1999). To date, no such algorithm has 
been prospectively evaluated (Schnarr & Smaill, 2008). 
3. Etiology and physiopathology 
3.1 Microbiology 
In normal physiological circumstances, the genito-urinary tract is sterile. The 
microorganisms causing UTIs usually originate from the gastro-intestinal flora of the host. 
For example, during pregnancy bacteriuria can occur when bacteria from a fecal source 
gains access to the bladder by ascending the relatively short female urethra (Patterson & 
Andriole, 1997). Patogens causing bacteriuria are similar in both pregnant and nonpregnant 
women (Schnarr & Smaill, 2008). Although virtually every organism can be associated with 
UTIs, certain organisms predominate as a result of specific virulence and host susceptibility 
factors (Joseph DiPiro et al., 2011).  
The most common agent implicated in uncomplicated UTIs is Escherichia coli, which 
accounts for 85% of non-hospital setting infections (Harris & Gilstrap, 1981; Millar & Cox, 
1997; Sharma & Thapa, 2007). Other microorganisms such as Staphylococcus saprophyticus 
(5% to 15% of cases) (Mittal & Wing, 2005), Gardnerella vaginalis, Chlamydia trachomatis, 
Klebsiella pneumoniae, Proteus spp., Pseudomonas aeruginosa, Enterococcus spp. (5% to 10%), 
Ureaplasma urealyticum and lactobacilli have also been associated with UTIs. Although the 
clinical significance of these organisms on UTIs during pregnancy was not yet appreciated, a 
few small studies have reported improved outcomes following therapy against these agents 
(Gilbert et al., 1986; Cohen et al., 1990). The consensus is that during gestation, most UTIs 
are caused by a single organism. Nevertheless, organisms isolated from pregnant women 
with complicated UTIs are more varied and generally are more resistant to treatment than 
those found in uncomplicated infections. Anaerobic and other fastidious microorganisms 
have been identified in the urine of a large percentage of pregnant women, but the role 
played by these organisms on adverse perinatal outcomes is unknown (Gilbert et al., 1986). 
There is evidence that some bacterial strains can replicate inside the cells, explaining the 
difficulties in treating some cases, given that these strains are protected from the action of 
anti-infective drugs (Rosen et al., 2007). At present, there is no evidence showing advantages 
in routinely examining the urine for these uncommon organisms. 
3.2 Physiopathology 
For many years, pregnancy was seen as a period that naturally predisposes to all forms of 
UTIs. This was explained by the fact that genito-urinary anatomical and physiological 
changes induced by gestation predispose women with asymptomatic bacteriuria to develop 
symptomatic UTIs, leading to the impression that the number of UTIs was higher during 
this period of life (Nowicki, 2002). Nowadays, it is known that gestation itself is not the only 
responsible for the increased risk of UTIs. Throughout pregnancy, UTIs often persist, owing 
to re-infection (Foxman & Brown, 2003). 
During gestation the urethra is colonized by bacteria originated from the gastro-intestinal 
and perineal flora (Naveen & Mathai, 2005). Other factors that can predispose urethral 
colonization include the use of some methods of contraception before pregnancy, such as 
spermicides and diaphragms (Fihn, 2003; Foxman & Brown, 2003). Although there is 
www.intechopen.com
 Urinary Tract Infections 116 
evidence that bladder infections follow colonization of the urethra, the mode of ascent of the 
microorganisms is not completely elucidated. After reaching the bladder, the organisms 
quickly multiply and can ascend the ureters to the kidneys. This sequence of events is more 
likely to occur if reflux of urine into the ureters and kidneys is present.  
Bacterial colonization is facilitated as early as the renal pelvis and ureters begin to dilate 
(eighth week of gestation), and the bladder is displaced superiorly and anteriorly inside the 
intra-abdominal cavity (Jeyabalan & Lain, 2007). Mechanical compression caused by the 
enlarging uterus is the principle cause of this dilatation, but smooth muscle relaxation 
induced by progesterone may also play a role. The main consequences of these changes are 
the decrease in peristalsis of the ureters, followed by an increase in bladder capacity and 
urinary stasis. It is known that the decreased renal capacity to concentrate urine during 
pregnancy reduces the antibacterial activity of this fluid, leading it to excrete smaller 
amounts of potassium and higher amounts of glucose, amino acids and hormone 
degradation products. These biochemical alterations turn the urine into an alkaline solution, 
thus providing a suitable environment for bacterial growth (Dafnis & Sabatini, 1992). 
Additionally, the increase in the estrogen induced by gestation, contribute to the adhesion of 
certain E. coli strains to the type 1 uroepithelial cells (Roos et al., 2006).  
Host protective factors such as the low glucose concentration of the urine, stability of the 
vaginal lactobacilli population, the influence of estrogens, the activity of Tamm-Horsfall 
protein, the presence of urinary mucus or slime (called glycosaminoglycan) and the 
immunologic defense mechanisms, makes the normal urinary tract generally resistant to 
invasion and efficient in rapidly eliminating microorganisms that reach the bladder (Parsons 
et al., 1978; Joseph DiPiro et al., 2011).  
Specific subsets of E. coli clones identified with O, K and H antigens were shown to have 
increased propensity to cause UTIs (Kaper, 2005; Naveen & Mathai, 2005). An important 
virulence factor of bacteria is their ability to adhere to urinary epithelial cells, resulting in 
colonization of the urinary tract, bladder infections, and pyelonephritis. Uropathogenic E. 
coli have such virulence factors, known as fimbrias or pilli. These are adherence proteins 
(adhesins) expressed on the bacterial wall surface that promote binding to the epithelium of 
the vagina and urethra, thus increasing E. coli ability to cause UTIs (Sandberg et al., 1988). 
Adhesins include type 1, S and P fimbriae, and adhesins like Dr (Kaper, 2005). This property 
was recognized decades ago, and it is what differentiates uropathogenic E. coli from the 
gastro-intestinal commensal forms (Eden et al., 1976).  
The type 1 fimbriae are prevalent and are probably involved in colonization of lower 
urinary tract (Naveen & Mathai, 2005). The role of P fimbriae in upper UTI is well 
documented (Wullt et al., 2002). These are present in 20% of faecal E. coli, 60% of cystitis 
causing, and 80% of E. coli isolated in pyelonehritis (Kaper, 2005). Attachment of P fimbriae 
to urinary tract epithelium is also associated with increased host inflammatory response 
(Wullt et al., 2002). Other factors that increase E. coli virulence include production of 
haemolysin, serum resistance and release of aerobactin (Wullt et al., 2002). Haemolysin 
provides E. coli a possible selective advantage by releasing iron from lysed erythrocytes and 
thus, enhancing pathogenicity by destroying phagocytic and epithelial cells (Naveen & 
Mathai, 2005). 
Animal models and human data suggest that E. coli can remain hidden in large bacterial 
reservoirs within the host and can be reactivated to cause infection in the future, when there 
is some local decrease in the normal activity of the host defense factors (Mulvey et al., 2001; 
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Epp et al., 2010). Midstream urine samples from women with acute uncomplicated cystitis 
also showed evidence of intracellular bacterial communities of uropathogenic E. coli (Rosen 
et al., 2007). These communities are relatively protected from host immune response 
mechanisms and antibiotic therapy. They may be reactivated, causing recurrent UTI (Rosen 
et al., 2007). 
There is some controversy concerning the role played by the physiological changes occuring 
during pregnancy which could be the main factor predisposing pregnant women to UTIs 
(Nowicki et al., 2011). Some authors claim that the biological complexity and molecular 
epidemiology of UTI suggest that mechanical obstruction can only partially explain the risk 
of developing gestational UTI (Nowicki, 2002). It is argued that if gestation alone 
predisposes to UTIs, urine stasis and obstruction should favour infection in the presence of 
avirulent random gram-negative and gram-positive species. Instead, 90% of gestational 
UTIs are associated with uropathogenic virulent E. coli strains, which (in contrast) are 
seldom isolated in the non-pregnant patients with urinary tract obstructive problems. To 
date, this issue remains controversial. 
4. Clinical presentation and diagnosis 
4.1 Clinical presentation 
Given that UTIs correspond to the growth and multiplication of bacteria within the urinary 
tract, the resulting lesions can result in different degrees of severity. These infections can be 
grouped into four different clinical entities, according to the anatomical location of injury, 
maintaining relations between them (see Introduction section). 
In 1962, Kass brought attention and concern to asymptomatic bacteriuria, noting that this 
form of infection was one of the most important predisposing factors for pyelonephritis in 
pregnant women (Kass, 1962). Since then, there was a step forward to recognize the 
importance of early diagnosis of this form of infection in early pregnancy, avoiding the 
complications of pyelonephritis (MacLean, 2001; Smaill, 2007). Asymptomatic bacteriuria is 
characterized by bacterial colonization of the urine, and if it shows no clinical symptoms, 
microbiological laboratory tests are needed to support its diagnosis (MacLean, 2001). 
Asymptomatic bacteriuria is defined by two consecutive clean-catch urine cultures with 
more than 108 colonies/L of urine, with a single type of bacteria (Shand et al., 1970). It is 
believed that the vast majority of pregnant women that developing UTIs’ symptomatic 
forms during gestation have asymptomatic bacteriuria at the time of conception. It was 
observed that 30% of women with asymptomatic bacteriuria developed symptomatic UTI 
during gestation (Gratacos et al., 1994). 
Urethritis is characterized by urethral colonization resulting in dysuria and polyuria. 
Approximately 50% of pregnant women suffering from this complication do not have 
significant asymptomatic bacteriuria, and in 30% of them, urine cultures are negative. From 
a practical standpoint, only 20% of symptomatic patients have urine culture with more than 
108 colonies/L of urine. Another important detail is that some etiological agents involved in 
urethritis are germs commonly found in the vaginal cavity and that cause genital infections - 
some cannot be detected in routine urine cultures, such as Chlamydia trachomatis and 
Mycoplasma hominis (Nicolle, 2006). However, the potential invasiveness of these bacteria in 
the urinary tract is low. 
Cystitis is the infection of the bladder, occurring in about 1 to 1.5% of pregnancies. Common 
clinical manifestations are dysuria, polyuria, suprapubic discomfort, and in some cases, 
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hematuria (Le et al., 2004). Although dysuria and polyuria may suggest UTIs, these 
symptoms may concomitantly be present in pregnant women with other conditions, such as 
bacterial vaginosis (Duarte et al., 2008). In addition, hemorrhagic cystitis during pregnancy 
can be confounded with bleeding issued from a process that could be bacterial, viral, fungal, 
immune (allergic) and radiotherapy. Cystitis is associated with preterm delivery and should 
be treated as soon as detected (Fakhoury et al., 1994). 
Pyelonephritis is the most severe form of UTI in pregnant women and may affect up to 2% 
of this population. Its occurrence is directly associated with the prevalence of asymptomatic 
bacteriuria among pregnant women (Gilstrap et al., 1981; Nowicki, 2002). This condition can 
occur with or without symptoms of cystitis. Overall, pyelonephritis is associated with worse 
maternal and prenatal prognosis (Schieve et al., 1994). Clinical signs and symptoms of 
pyelonephritis include flank pain (unilateral or bilateral) or abdominal pain, fever, anorexia, 
nausea and vomiting often associated with variable degrees of dehydration, chills, 
headache, and tachypinea. Respiratory failure and sepsis can be present in severe forms. 
Fever is elevated in the acute forms (Rosen et al., 2007). When considering the clinical 
diagnosis of UTIs during pregnancy, it is useful to remember that some symptoms of 
infection are difficult to characterize because they can be normally present during gestation, 
such as polyuria. In addition, asymptomatic bacteriuria does not present any clinical 
manifestation. However, patient history and risk factors can identify women at higher risk 
of UTI (Pastore et al., 1999; Nowicki, 2002; Fatima & Ishrat, 2006; Roos et al., 2006).  
4.2 Diagnosis 
Given the increased incidence of symptomatic UTI during pregnancy and its association 
with maternal and perinatal complications, screening of asymptomatic bacteriuria during 
pregnancy is requested with two urine samples obtained at different times. Testing a single 
sample may provide false-positive result in up to 40% of cases (MacLean, 2001). This 
measure can allow early start treatment and reduces the rate of progression to symptomatic 
infection and it’s potentially harmfull consequences (Gratacos et al., 1994; Smaill, 2007).  
Current laboratory tests for the diagnosis of UTI are based on the color changes of chemical 
reactants according to urine composition (dipstick analysis). Two of these are important for 
their rapidity and low costs: the test of nitrite and the test of leukocyte esterasis. The nitrite 
test is based on the ability of certain bacteria to reduce the urinary nitrate to nitrite. This test 
has 50% sensitivity and specificity of 97%, and can result in false positives when used on 
urine contaminated by normal vaginal bacteria or highly concentrated urine, given that the 
test follows colorimetric principles. The leukocyte esterase test has low sensitivity and 
specificity (25%) and can also result in false positives. Both tests have low sensitivity and 
therefore not suitable as screening tests for diagnosis, unless they are used in combination 
with other tests (McNair et al., 2000). 
Microscopic urinalysis is the examination of one drop of centrifuged and uncoloured fresh 
urine, with dry objective (400 times magnification). The observation of any bacteria per field 
correlates with a urine culture of at least 108 colonies/L of urine. Despite being a low cost 
test, its low sensitivity limits it to be indicated in the screening of asymptomatic bacteriuria 
(McNair et al., 2000). Current evidence seems to indicate that the microscopic analysis of a 
Gram-colored urine sample is a more suitable and rapid test for UTI screening. It consists in 
the microscopic observation of the urine bacteria Gram stain, improving the accuracy of 
microscopic urinalysis (Duarte et al., 2008). 
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Several alternative laboratory methods can be used for the diagnosis of UTIs with varying 
sensitivities and specificities. Therefore, the association of these tests can be necessary to 
confirm the positive results of a urinalysis. Moreover, for their meaningfull interpretation, it 
become imperative to use correct techniques for collecting the urine sample (aseptic perineal 
urine midstream, immediate transportation and refrigeration at 4 °C for, no later than 24 
hours) (Nicolle, 2006). 
Among the abnormalities likely to be detected in a urinalysis, we can find pyuria, 
hematuria, proteinuria and cylinders in the urinary sediment. These findings can indicate 
UTI, but actually they are just signs of inflammation and may also be present in other 
conditions. It should be remembered that a normal urinalysis result does not exclude the 
diagnosis of UTI, hence, not being ideal for screening of asymptomatic bacteriuria during 
pregnancy. However, in symptomatic patients, the result of this test is accepted for the 
initiation of therapy until the results of urine microbiologic culture are known (Nicolle, 2006; 
Duarte et al., 2008). 
The urine microbiologic culture is considered the gold standard for laboratory diagnosis 
of UTI. It is the most accurate method to identify and quantify bacteria in the urine with 
high sensibility (MacLean, 2001). Its drawbacks are the relatively higher costs, the long 
time needed to achieve the number of bacterial colonies necessary for a sensitive result 
and the need for professionals and laboratories qualified for its elaboration (Rosen et al., 
2007). The correct interpretation of a urine culture is crucial for therapeutic success. In 
asymptomatic cases, the finding of more than 108 colonies/L of urine suggests infection. 
Values between 107 and 108 correspond to infection in 50% of cases. If the urine is collected 
by bladder catheterization, the finding of values above 106 indicates infection; if the urine 
is issued by suprapubic aspiration, infection is diagnosed with any number of bacteria. In 
symptomatic cases, urine cultures are considered positive with up to 105 bacteria/mL of 
urine (Nicolle, 2006). 
Other important complementary tests include total and differential blood cells count, and 
dosage of metabolites such as urea and creatinine. These tests help to identify the severity 
of the infection, reflected in the hematologic and renal function parameters. However, 
they are not essential for the monitoring of patients with uncomplicated UTIs. Ultrasound 
of kidneys and urinary tract can be considered an important complementary examination. 
In addition of being rapid, inexpensive, easily accessible and totally safe for both mother 
and fetus, they can help to identify predisposing factors for adverse pregnancy outcomes, 
such as urinary calculus and pathological dilatation of the renal collecting system (Duarte 
et al., 2008). 
5. UTIs and pregnancy outcomes 
Several studies have associated UTIs during gestation with the risk of adverse perinatal and 
maternal outcomes. Some other studies failed to prove such associations (Gilstrap et al., 
1981; Reddy & Campbell, 1985; Chen et al., 2010). Inconsistencies in the results of these 
studies could be due to selection bias, low statistical power and inadequate control for 
potential confounders. As stated before, the general consensus is that UTIs can lead to 
complications, such as low-birth-weight infants, premature delivery, and, occasionally, 
stillbirth (Lee et al., 2008).  
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5.1 UTIs and maternal outcomes 
The maternal complications of UTI are a result of the tissue damage caused by bacterial 
endotoxins, especially in pyelonephritis (Neal, 2008). The most dramatic maternal 
complication associated with UTIs is bacteremia and septic shock, induced by resistant 
pyelonephritis (Mittal & Wing, 2005).  Endotoxin-mediated damage includes diminished 
peripheral vascular resistance and changes in cardiovascular output. With the release of 
E. coli endotoxin active component of (lipid A) into the maternal circulation, a cascade 
response of pro-inflammatory cytokines, histamine, and bradykinins is precipitated, 
which may lead to the more serious complications (septic shock, disseminated 
intravascular coagulation, respiratory insufficiency, and adult respiratory distress 
syndrome (Galajdova, 2010)). This syndrome is defined as a disease of acute onset with 
bilateral infiltrates on chest radiograph and hypoxemia without evidence of pulmonary 
hypertension (Graves, 2002), and complicates 1% to 8% of cases of pyelonephritis in 
pregnancy (Wing, 1998). Women who have septic shock require admission to intensive 
care, immediate fluid resuscitation, and antimicrobial therapy. Although patients 
generally respond well to oxygen therapy, worsening dyspnea, tachypnea, and 
hypoxemia may signify progress to adult respiratory distress syndrome (Graves, 2002). 
Respiratory failure and pulmonary edema can result from an increased permeability of 
the alveolar-capillary membrane. This condition can be worsened by the use of 
hyperhydration and tocolytics, often administered for inhibition of preterm labor (Duarte 
et al., 2008). Although bacteremia is detected in 15-20% of women with severe 
pyelonephritis, few of them develop clinical manifestations of septic shock. 
Other maternal complications that have been associated with UTIs during pregnancy are 
hypertension and preeclampsia (Conde-Agudelo et al., 2008; Rustveld et al., 2008), anemia 
(Fede, 1983), chorioamnionitis and endometritis (Schieve et al., 1994; Delzell & Lefevre, 
2000). The causal nature of these associations is questionable, because it is not always clear 
whether an episode of UTI preceded the particular outcome of interest, especially in what 
concerns maternal hypertension and anemia (Schieve et al., 1994). 
The relationship between UTIs during pregnancy and preeclampsia is consistent throughout 
studies performed over the last years, and is present in diverse settings worldwide (Conde-
Agudelo et al., 2008). Several mechanisms have been proposed to explain how maternal 
infection might be involved in the etiology of preeclampsia or its manifestations. These 
include direct effects of the infectious agents on the arterial walls, including endothelial 
injury or dysfunction, acute atherosis, and local inflammation that might cause relative 
uteroplacental ischemia (von Dadelszen & Magee, 2002). Furthermore, some authors have 
hypothesized that the infection might be involved in both the initiation of the pre-eclampsia 
process (by increasing the risk of acute uteroplacental atherosis) and/or its potentiation (by 
amplifying the maternal systemic inflammatory response) (Herrera et al., 2001). 
Nevertheless, these hypotheses are issued from animal data and some other authors argue 
that the association between UTIs and preeclampsia may not be real and may be due to 
confounding. For example, abnormal changes associated with chronic pyelonephritis and 
papillary necrosis has been observed in almost half of women with bacteriuria during 
pregnancy (Whalley et al., 1965). These underlying diseases and the impairment of renal 
function they cause could, thus, account for the higher risk of preeclampsia among women 
with bacteriuria (Conde-Agudelo et al., 2008). More data is needed to determine whether the 
relationship between maternal UTIs and preeclampsia is causal. 
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Local complications, such as urinary obstruction, perinephric abscess and cellulitis are rare 
and when present, are associated with lithiasis or treatment-resistant microorganisms (Le et 
al., 2004; Neal, 2008). 
5.2 UTIs and perinatal outcomes 
The association between perinatal outcomes and UTIs has been studied for many years 
(Mittal & Wing 2005; Duarte et al., 2008). From a global health perspective, UTI is one of 
the most important and potentially preventable causes of early preterm birth (Simmons et 
al., 2010). Intrauterine infections are thought to be responsible for up to 50% of extreme 
preterm births of less than 28 weeks of gestation, where both neonatal mortality and 
morbidity are high (Simmons et al., 2010). Observational studies show an association 
between maternal UTIs and preterm birth and low birth weight (Gravett et al., 2010). Most 
of these studies are conducted in lower and middle income countries. Therefore, there is a 
great deal of heterogeneity between studies regarding the association between these 
infections and the risk of preterm birth (Beck et al., 2010). Among other recognized 
perinatal complications of UTI, we highlight premature rupture of membranes, 
intrauterine growth restriction, cerebral palsy/mental retardation and perinatal death 
(Romero et al., 1989; Polivka et al., 1997; McDermott et al., 2000; Duarte et al., 2008). Some 
cases of periventricular leukomalacia and fetal septicemia have been recently reported as 
a result of transplacental transfer of cytokines originated from maternal UTIs (Spinillo et 
al., 1998; Oda et al., 2008). Pregnancies complicated by UTIs are also associated with 
increased fetal mortality (McDermott et al., 2001). 
It was estimated that 27% of preterm deliveries are associated with pre-existing UTIs 
(Turiani, 2009). In the same study, the investigators found that women with pyelonephritis 
had prevalence for low birth weight infants of 15% (defined as birth weight less than 2500 
grams).  Same findings were reported in a large cohort study conducted in the USA. In this 
study, UTIs were also associated with the risk of small-for-gestational-age newborns 
(Schieve et al., 1994). Evidence issued from microbiological analysis of the genito-urinary 
tract of women with premature labor or preterm rupture of membranes, show that UTI is 
the most important risk factor for perinatal morbidity and fetal death (Turiani, 2009). Data 
from 52 cases of neonatal sepsis showed that UTIs were present in 63% of cases 
(Ananthakrishnan & Gunasekaran, 2009). All the aforementioned adverse pregnancy 
outcomes are important predictors of neonatal mortality.  
Data on the treatment of UTI and its effect on pregnancy outcomes corroborate the 
observation that these infections, if left untreated, are associated with low birth weight. In 
one study, the risk of preterm delivery in women who had asymptomatic UTI was two 
times greater than in unaffected women. With adequate treatment, the risk of low birth 
weight infants was 44% lower when compared to the untreated group (Gilstrap et al., 1981; 
Romero et al., 1989). These findings were confirmed in a recent Cochrane review which 
demonstrated the decreased incidence of pyelonephritis and low birth weight infants when 
asymptomatic UTI was treated (Smaill & Vazquez, 2007). 
The increased incidence of preterm labor and delivery associated with UTIs can be 
explained by the inflammatory response induced by citokines and prostaglandins 
mediators. Another way in which preterm labor can be triggered is through the colonization 
of amniotic fluid by uropathogens originated from UTIs. These bacteria produce 
phospholipases A and C, that act as precursors of pro-contractile prostaglandins E2 and F2a, 
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consequently triggering preterm labor (Duarte et al., 2008; Bhutta et al., 2010). There are 
several mechanisms suggested to explain the high rates of premature rupture of membranes 
in pregnant women with UTI. One of them is that UTIs induces the release of 
metalloproteinases by macrophages, via cytokines which degrade the membranes, 
predisposing them to rupture, in a similar way as do collagenasis and phospholipasis issued 
from bacteria (Sayres, 2010) (Wax et al., 2010). 
There has also been a hypothesis suggesting that UTI during pregnancy is associated with 
child developmental delay and mental retardation (Broman, 1987). One study has found a 
30% increase in the risk for cognitive delay in children whose mothers had UTI during 
pregnancy, when compared to children whose mothers were not infected (McDermott et al., 
2001). Furthermore, when comparing untreated women with treated women, the risk of 
having infants with cognitive delay was 22% higher. These results support the association 
between UTI in pregnancy and cognitive delay and emphasize the importance of the rapid 
diagnosis and treatment. However, the multifactorial nature of these outcomes makes the 
determination of etiology difficult, and no firm consensus has been reached on this subject 
(Mittal & Wing 2005). 
Given the burden of UTI during pregnancy, with regards to adverse maternal and 
pregnancy outcomes, these infections must be adequately diagnosed and efficient treatment 
must be initiated. Screening and treatment of assympomatic UTI during pregnancy is 
recommended by the U.S. Preventive Services Task Force (USPSTF, 2010). Given the 
evidence indicating that detection and treatment of asymptomatic bacteriuria with 
antibiotics significantly reduces the incidence of maternal UTIs and low birth weight, the 
USPSTF concludes that during pregnancy, there is high certainty that the net benefit of 
screening for asymptomatic bacteriuria is substantial. Nevertheless, in men and non-
pregnant women, there is moderate certainty that the harms of screening for asymptomatic 
bacteriuria outweighs the benefits (Lin & Brown, 2010). The USPSTF discloses that the urine 
culture is the standard criterion for detecting asymptomatic bacteriuria. Nevertheless, as 
previously discussed, it is recognized that this test is expensive for routine screening in 
populations with a low prevalence of the condition. However, no currently available tests 
have a high enough sensitivity and negative predictive value (Lin & Fajardo, 2008). The 
screening tests used commonly in primary care (dipstick analysis and direct microscopy) 
have poor positive and negative predictive value for detecting bacteriuria in asymptomatic 
persons (Bandyopadhyay et al., 2005, 2010). Pregnant women with asymptomatic 
bacteriuria should receive antibiotic therapy directed at the cultured organism and follow-
up monitoring. The screening intervals must be between 12 to 16 weeks' gestation or at the 
first pre-natal visit, if later, although there is no consensus in the literature as to the optimal 
timing and screening frequency for asymptomatic bacteriuria (McIsaac et al., 2005; Tugrul et 
al., 2005; Schnarr & Smaill, 2008). 
6. Treatment of UTIs during pregnancy 
Data from observational studies showed that the prevalence of anti-infective use during 
pregnancy is 24.5% (Santos et al., 2010a). Once the clinical diagnosis of UTI is established, 
treatment is mandatory even when no confirmation of the UTI etiological agent by the 
microbiologic culture test is available. As a consequence, the initial antibiotic therapy has 
the drawback of being empirical, and a variety of different antimicrobial agents can be 
used for the treatment of bacteriuria (Gilstrap & Ramin, 2001). Therefore, a periodic 
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assessment of the sensitivity pattern of etiological agents against anti-infective drugs 
commonly used to treat UTIs must be done. This measure becomes extremely important 
given the growing number of bacterial resistant to the antibiotics that are deemed safe 
during pregnancy (Duarte et al., 2008). It is important to remember that therapy must be 
safe for both mother and fetus. Nearly all anti-infective drugs are able to cross the 
placenta, and therefore agents that may be harmful to the developing fetus should be 
avoided. Antibiotics that have been associated with teratogenic effects are quinolones, 
trimethropime/sulfamethoxazole, chloramphenicol, and tetracycline (Macejko & 
Schaeffer, 2007).  
Quinolones has been associated to the development of arthropathy when given directly to 
immature animals and is not usually recommended for routine use during pregnancy. This 
adverse effect has not been described in humans (Gilstrap & Ramin, 2001; Macejko & 
Schaeffer, 2007; Lee et al., 2008). Tetracycline has been associated with yellow-brown 
discoloration of the deciduous teeth, when used after the 16th week of gestation, and 
gentamicin could potentially cause eighth nerve damage in the fetus (Dashe & Gilstrap, 
1997; Schnarr & Smaill, 2008). 
Given that pregnant women are not enrolled in randomised clinical trials assessing safety, 
there is no clear consensus on the choice of antibiotics and the duration of treatment during 
gestation. As a consequence, practice is more likely guided by national patterns of 
prescription and local bacterial resistance profiles (Schnarr & Smaill, 2008). Antibiotics 
commonly used for the treatment of UTIs during pregnancy have not been found to be 
associated with an increased risk of birth defects. Beta lactams antibiotics, such as penicillins 
and cephalosporins, are deemed safe during pregnancy and are commonly prescribed for 
the treatment of UTIs during the gestational period (Lee et al., 2008; Schnarr & Smaill, 2008; 
Guinto et al., 2010, Santos et al., 2010a). Despite the fact that no drug of this class has any 
apparent teratogenic properties, beta-lactams are sometimes associated with allergic and 
anaphylactic reactions. In addition, high bacterial resistance rates limit the use of some 
agents, such as amoxicillin or ampicillin (Dashe & Gilstrap, 1997; Guinto et al., 2010).  
Safety of nitrofurantoin in pregnancy has already been demonstrated (Ben David et al., 
1995). Nitrofurantoin only achieves therapeutic levels in the urine, so it cannot be used to 
treat pyelonephritis. This drug is not active against Proteus spp (Christensen, 2000; Sahm et 
al., 2001). There is a theoretical risk of nitrofurantoin-induced hemolytic anemia in the 
fetusor newborn, particularly in those with glucose-6-phosphate dehydrogenase (G6PD) 
deficiency (Smaill & Vazquez, 2007; Guinto et al., 2010). 
Trimethoprim is a folic acid antagonist and its use during the first trimester has been 
associated with neural tube and cardiovascular defects in the newborn (Milo et al., 2005). 
Sulfonamides could theoretically displace bilirubin from albumin-binding sites and could 
cause severe jaundice leading to kernicterus. Practical evidence of this risk, however, is 
sparse (Smaill, 2000). Furtheremore, a recent study showed an association between exposure 
to sulphonamides during the last two trimesters of pregnancy and the risk of small for 
gestational age newborns (Santos et al., 2010b). 
Follow-up of women with asymptomatic bacteriuria is important because approximately 
one third of them will experience a recurrent infection during pregnancy. For women with 
frequent recurrent episodes of bacteriuria or symptomatic UTIs, prophylactic continuous 
antibiotic treatment should be considered. However, the protracted use of antibiotics, 
especially ampicillin and cephalosporins, may interfere with the normal gastrointestinal 
flora. Prolonged use of these antibiotics may be associated with chronic vulvovaginitis 
secondary to overgrowth of Candida albicans (Gilstrap & Ramin 2001). 
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Table 1 summarizes most common therapeutic regimens currently proposed for the 
treatment of UTIs during pregnancy, according to the type of UTIs (Bruel et al., 2000; Milo et 
al., 2005; Mittal & Wing, 2005; Cimolai & Cimolai, 2007; Rosen et al., 2007; Duarte et al., 2008; 
Guinto et al., 2010). 
 
Urinary tract 
infection 
Treatment regimen Treatment options Comments 
Assymptomatic 
bacteriuria 
Current standard 
of practice is to 
treat pregnant 
patients who have 
asymptomatic 
bacteriuria with at 
least 3 to 7 days of 
an oral anti-
infective agent 
(Rubin et al., 1992; 
Connolly & Thorp, 
1999; Christensen, 
2000; Gilstrap & 
Ramin, 2001; 
Ovalle & 
Levancini, 2001). 
Cephalexin 250-500 mg, 
po, qid 
Nitrofurantoin 100 mg, 
po, qid or  
Nitrofurantoin 
(monohydrate/macro-
crystals) 100 mg, po, 
bid, 7 days 
Amoxicillin 500 mg, po, 
tid 
Norfloxacin 400 mg, po, 
bid 
Cefuroxim 250 mg, po, 
tid 
SXT (320/1600 mg) po, 
once a day (avoid use 
during first trimester) 
Single-dose and three days regimens 
have been used, but showed lack of 
efficacy. Some authors do not 
recommend during gestation (Rubin et 
al., 1992; Smaill & Vazquez, 2007). 
SXT was associated with a theoretical 
increased risk of neural tube defects 
and it may lead to neonatal kernicterus 
(Schnarr & Smaill, 2008). 
Nitrofurantoin was associated with 
theoretical risk of fetal hemolytic 
anemia when mother has G6PD 
deficiency (Smaill & Vazquez, 2007). 
Given the increased rates of bacterial 
resistance to ampicillin and 
cephalexin, one must verify hospital 
susceptibilities before prescribing b-
lactam monotherapy (Mittal & Wing, 
2005; Joseph DiPiro et al., 2011). 
Urethritis and 
cystitis 
Given that the 
pathogens 
associated with 
urethritis and 
cystitis are the 
same as those 
causing  
asymptomatic 
bacteriuria, the 
treatment of 
cystitis in 
pregnancy is the 
same as the 
treatment for 
asymptomatic 
bacteriuria, longer 
courses of therapy 
are usually 
recommended (7-
10 days) (Gilstrap 
& Ramin, 2001). 
Cefuroxim 250 mg, po, 
tid 
Nitrofurantoin 100 mg, 
po, qid or  
Nitrofurantoin 
(monohydrate/macro-
crystals) 100 mg, po, bid 
Amoxicillin 500 mg, po, 
tid 
SXT (320/1600 mg) po, 
once a day (avoid use 
during first trimester) 
These agents are FDA class B category 
(Mittal & Wing, 2005). 
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Urinary tract 
infection 
Treatment regimen Treatment options Comments 
Pyelonephritis 
Initial treatment 
must be 
parentheral 
(Vazquez & Villar, 
2003;  Duarte et al., 
2008). First-line 
therapy often 
includes a first-
generation 
cephalosporin. In 
an inpatient 
setting, parenteral 
antimicrobial 
therapy usually is 
continued until the 
patient is afebrile 
for 48 hours 
(Wing, 1998). The 
patient is switched 
to oral 
antimicrobial 
therapy for 2 
weeks (total). 
Ampicillin 2 grams, IV, 
q6h (+) Gentamicin 1.5-
1.7/mg/kg, IV, q6 h 
Gentamicin 1.5-
1.7/mg/kg, IV, q8h 
Ampicillin-sulbactam 3 
grams, IV, q6 h 
Ceftriaxone 1 gram, 
IV/IM, q24 h 
Cefuroxime 0.75–1.5 
grams, IV, q8 h 
Cefazolin 2 grams, IV, 
q6–8 h 
Mezlocillin 3 grams, IV, 
q6 h 
Piperacillin 4 grams IV 
q8 h 
Ticarcillin/clavulanate 
3.1 grams, IV, q6h 
Ampicillin monotherapy showed high 
incidence of resistant bacteria, and 
therefore, usually is used in 
conjunction with gentamicin (Dunlow 
& Duff, 1990). 
To avoid exacerbation of the renal 
insufficiency that commonly 
accompanies pyelonephritis, drug 
serum levels should be monitored 
when using aminoglycosides, such as 
gentamicin (Wing, 1998). 
Table 1. Most common therapeutic regimens currently proposed for the treatment of UTIs 
during pregnancy (Abbreviations: po: by mouth; q: every; bid: twice a day; tid: three times a 
day; qid: four times a day; SXT: Trimethoprim/Sulfamethoxazole; IM: intramuscularly; IV: 
intravenously). 
7. Conclusion 
Urinary tract infection is a prevalent complication of pregnancy that can worsen maternal 
and perinatal prognosis. Untreated asymptomatic forms can progress to pyelonephritis, 
which is associated with preterm delivery, low birth weight infants and stillbirth. In 
addition to the increased incidence of UTIs during gestation, health care professionals must 
be aware that the choice of available anti-infective drugs are restricted, given the risk of 
certain of them for the fetus, and the potential for bacterial resistance. Most of the drugs 
used for the treatment of UTIs during pregnancy are not associated with an increased risk of 
birth defects. Early diagnosis followed by immediate and adequate therapy is essential 
during gestation, avoiding compromising maternal and neonatal health. 
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